Monitor HREC submission in November 2026 and first patient dosing in April 2027 as key catalysts for PRP. The $100M private placement facility provides runway but dilutive overhang remains. No revenue or earnings guidance to trade on.
Price Chart
Executive Summary
Propanc Biopharma reported a year-end net loss of $18.86M for FY2026, improved from a $58.92M loss in FY2025, with zero revenue. The company is advancing its lead candidate PRP toward a Phase 1b first-in-human study in Q1 2027, supported by $7.5M in gross proceeds raised during the year and a $100M private placement facility. The filing is a clinical-stage biotech update with no earnings surprise to trade on.
Key Financial Metrics
Key Facts
- Net loss for FY2026 was $18.86M, improved from $58.92M in FY2025
- Zero revenue reported for both FY2026 and FY2025
- Cash at June 30, 2026 was $832,006, up from $12,088 a year earlier
- Raised $7.5M gross proceeds in FY2026, including a $4.0M underwritten public offering
- Entered a $100M private placement facility; received $4.0M initial investment as of June 30
- Phase 1b FIH study of PRP expected to commence in Q1 2027, enrolling up to 50 patients
- Preclinical data showed >90% tumor growth inhibition and >2.5-fold survival extension in PDAC models
- Share repurchase program of up to $5.0M authorized; first tranche of $500,000 completed
Financial Impact
Net loss improved by $40.06M year-over-year; cash position increased by $819,918; total assets $12.78M
Risk Factors
- Pre-revenue clinical-stage company with no approved products or revenue stream
- Dilution risk from $100M private placement facility and Series C convertible preferred stock
- Clinical trial execution risk for Phase 1b FIH study of PRP
- Accumulated deficit of $144.5M as of June 30, 2026
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3370837 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | Press Release | $0.2800 | awaiting T+5 | — | $2.21 (+689.29%) |
Oct 5, 2026 21d ago | S-1 | $0.4913 $0.4125 | ▲ +16.04% | ▲ +15.90% | $2.21 (−349.83%) |
Sep 29, 2026 28d ago | Press Release | $0.5123 $0.4913 | ▼ −4.10% | ▼ −6.05% | $2.21 (+331.39%) |
Aug 18, 2026 10w ago | Press Release | $1.16 $1.13 | ▼ −2.59% | ▼ −2.39% | $2.21 (+90.52%) |
Jul 14, 2026 14w ago | 8-K | $1.63 $1.44 | ▼ −11.66% | ▼ −10.68% | $2.21 (+35.58%) |
May 19, 2026 23w ago | Press Release | $2.01 $1.62 | ▼ −19.20% | ▼ −21.45% | $2.21 (+10.22%) |
May 15, 2026 23w ago | Press Release | $1.70 $1.76 | ▲ +3.53% | ▲ +2.57% | $2.21 (+30.00%) |
May 13, 2026 23w ago | Press Release | $1.83 $1.73 | ▼ −5.34% | ▼ −4.62% | $2.21 (+20.93%) |
Apr 21, 2026 27w ago | EFFECT | $2.83 $2.65 | ▼ −6.28% | ▼ −7.36% | $2.21 (−21.84%) |
Mar 24, 2026 31w ago | Press Release | $2.77 $2.65 | ▼ −4.33% | ▼ −3.91% | $2.21 (−20.22%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers